The company reported an increase in revenue from operations, driven by strong performance in its Contract Development and Manufacturing Organization and India Consumer Healthcare segments. EBITDA margins improved significantly, reflecting operational efficiencies and cost optimization initiatives throughout the year. The net debt to EBITDA ratio also showed improvement, indicating better financial health as the company ended the fiscal year with a lower ratio compared to the previous year.
Piramal Pharma Limited has informed the Exchange regarding a press release dated May 10, 2024, titled "Press Release and Investor Presentation Audited Financial Results (Standalone & Consolidated) of the Company for the quarter and year ended 31st March, 2024".